25 XP   0   0   10

Sonnet Biotherapeutics Holdings Inc
Buy, Hold or Sell?

Let's analyse Sonnet Biotherapeutics Holdings Inc together

PenkeI guess you are interested in Sonnet Biotherapeutics Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sonnet Biotherapeutics Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sonnet Biotherapeutics Holdings Inc

I send you an email if I find something interesting about Sonnet Biotherapeutics Holdings Inc.

Quick analysis of Sonnet Biotherapeutics Holdings Inc (30 sec.)










What can you expect buying and holding a share of Sonnet Biotherapeutics Holdings Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
17.5%

What is your share worth?

Current worth
$0.68
Expected worth in 1 year
$2.51
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$1.83
Return On Investment
101.1%

For what price can you sell your share?

Current Price per Share
$1.81
Expected price per share
$1.5334 - $2.6099
How sure are you?
50%

1. Valuation of Sonnet Biotherapeutics Holdings Inc (5 min.)




Live pricePrice per Share (EOD)

$1.81

Intrinsic Value Per Share

$-54.23 - $16.34

Total Value Per Share

$-53.55 - $17.02

2. Growth of Sonnet Biotherapeutics Holdings Inc (5 min.)




Is Sonnet Biotherapeutics Holdings Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$2.5m$805.3k$1.9m71.1%

How much money is Sonnet Biotherapeutics Holdings Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.6m-$7.2m$3.6m100.9%
Net Profit Margin-10,603.8%-11,986.3%--

How much money comes from the company's main activities?

3. Financial Health of Sonnet Biotherapeutics Holdings Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#811 / 1019

Most Revenue
#677 / 1019

Most Profit
#375 / 1019

Most Efficient
#949 / 1019

What can you expect buying and holding a share of Sonnet Biotherapeutics Holdings Inc? (5 min.)

Welcome investor! Sonnet Biotherapeutics Holdings Inc's management wants to use your money to grow the business. In return you get a share of Sonnet Biotherapeutics Holdings Inc.

What can you expect buying and holding a share of Sonnet Biotherapeutics Holdings Inc?

First you should know what it really means to hold a share of Sonnet Biotherapeutics Holdings Inc. And how you can make/lose money.

Speculation

The Price per Share of Sonnet Biotherapeutics Holdings Inc is $1.81. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sonnet Biotherapeutics Holdings Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sonnet Biotherapeutics Holdings Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.68. Based on the TTM, the Book Value Change Per Share is $0.46 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.62 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sonnet Biotherapeutics Holdings Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.31-17.0%-1.16-64.1%-2.37-130.8%-2.52-139.2%-1.42-78.3%
Usd Book Value Change Per Share0.7541.5%0.4625.3%-1.62-89.7%-0.07-4.0%-0.05-2.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.031.6%0.020.9%
Usd Total Gains Per Share0.7541.5%0.4625.3%-1.62-89.7%-0.04-2.3%-0.03-1.8%
Usd Price Per Share1.74-1.36-0.82-1.33-1.63-
Price to Earnings Ratio-1.41--0.54--0.09--0.26--1.13-
Price-to-Total Gains Ratio2.32--0.19--1.29-27.95-18.55-
Price to Book Ratio2.57--8.93--0.38--0.01-0.42-
Price-to-Total Gains Ratio2.32--0.19--1.29-27.95-18.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.81
Number of shares552
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share0.46-0.07
Usd Total Gains Per Share0.46-0.04
Gains per Quarter (552 shares)252.50-23.35
Gains per Year (552 shares)1,010.01-93.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101010100065-158-103
2020202010130-317-196
3030303020195-475-289
4040404030259-633-382
5050505040324-791-475
6060606050389-950-568
7070707060454-1108-661
8080808070519-1266-754
9090909080584-1424-847
1001010010090648-1583-940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.051.00.01.9%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%7.012.01.035.0%11.027.02.027.5%18.032.02.034.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%4.00.016.020.0%7.00.033.017.5%7.00.045.013.5%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%8.012.00.040.0%13.026.01.032.5%20.031.01.038.5%

Fundamentals of Sonnet Biotherapeutics Holdings Inc

About Sonnet Biotherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

Fundamental data was last updated by Penke on 2024-04-12 18:51:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sonnet Biotherapeutics Holdings Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sonnet Biotherapeutics Holdings Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sonnet Biotherapeutics Holdings Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -6,273.5% means that $-62.74 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is -6,273.5%. The company is making a huge loss. -2
  • The TTM is -10,603.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-6,273.5%TTM-10,603.8%+4,330.3%
TTM-10,603.8%YOY-11,986.3%+1,382.5%
TTM-10,603.8%5Y-4,797.9%-5,805.9%
5Y-4,797.9%10Y-2,410.1%-2,387.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6,273.5%-196.9%-6,076.6%
TTM-10,603.8%-211.2%-10,392.6%
YOY-11,986.3%-279.3%-11,707.0%
5Y-4,797.9%-436.8%-4,361.1%
10Y-2,410.1%-599.3%-1,810.8%
1.1.2. Return on Assets

Shows how efficient Sonnet Biotherapeutics Holdings Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sonnet Biotherapeutics Holdings Inc to the Biotechnology industry mean.
  • -21.9% Return on Assets means that Sonnet Biotherapeutics Holdings Inc generated $-0.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is -21.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -42.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.9%TTM-42.9%+21.0%
TTM-42.9%YOY-99.8%+56.9%
TTM-42.9%5Y-83.4%+40.5%
5Y-83.4%10Y-44.8%-38.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.9%-13.6%-8.3%
TTM-42.9%-12.9%-30.0%
YOY-99.8%-11.9%-87.9%
5Y-83.4%-14.2%-69.2%
10Y-44.8%-16.2%-28.6%
1.1.3. Return on Equity

Shows how efficient Sonnet Biotherapeutics Holdings Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sonnet Biotherapeutics Holdings Inc to the Biotechnology industry mean.
  • -45.4% Return on Equity means Sonnet Biotherapeutics Holdings Inc generated $-0.45 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is -45.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -66.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-45.4%TTM-66.6%+21.2%
TTM-66.6%YOY-282.1%+215.4%
TTM-66.6%5Y-286.7%+220.1%
5Y-286.7%10Y-151.6%-135.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-45.4%-17.0%-28.4%
TTM-66.6%-16.1%-50.5%
YOY-282.1%-15.4%-266.7%
5Y-286.7%-20.0%-266.7%
10Y-151.6%-21.1%-130.5%

1.2. Operating Efficiency of Sonnet Biotherapeutics Holdings Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sonnet Biotherapeutics Holdings Inc is operating .

  • Measures how much profit Sonnet Biotherapeutics Holdings Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sonnet Biotherapeutics Holdings Inc to the Biotechnology industry mean.
  • An Operating Margin of -6,866.1% means the company generated $-68.66  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is -6,866.1%. The company is operating very inefficient. -2
  • The TTM is -10,601.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6,866.1%TTM-10,601.8%+3,735.7%
TTM-10,601.8%YOY-12,027.1%+1,425.3%
TTM-10,601.8%5Y-4,806.5%-5,795.2%
5Y-4,806.5%10Y-2,414.4%-2,392.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6,866.1%-282.4%-6,583.7%
TTM-10,601.8%-225.8%-10,376.0%
YOY-12,027.1%-288.4%-11,738.7%
5Y-4,806.5%-475.2%-4,331.3%
10Y-2,414.4%-624.7%-1,789.7%
1.2.2. Operating Ratio

Measures how efficient Sonnet Biotherapeutics Holdings Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 69.66 means that the operating costs are $69.66 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is 69.661. The company is inefficient in keeping operating costs low. -1
  • The TTM is 108.134. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ69.661TTM108.134-38.473
TTM108.134YOY144.218-36.084
TTM108.1345Y50.133+58.001
5Y50.13310Y25.402+24.731
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ69.6612.994+66.667
TTM108.1343.247+104.887
YOY144.2183.766+140.452
5Y50.1335.675+44.458
10Y25.4027.857+17.545

1.3. Liquidity of Sonnet Biotherapeutics Holdings Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sonnet Biotherapeutics Holdings Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.74 means the company has $1.74 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is 1.742. The company is able to pay all its short-term debts. +1
  • The TTM is 1.442. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.742TTM1.442+0.300
TTM1.442YOY1.152+0.289
TTM1.4425Y1.298+0.144
5Y1.29810Y0.770+0.528
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7423.930-2.188
TTM1.4424.251-2.809
YOY1.1525.436-4.284
5Y1.2986.045-4.747
10Y0.7706.383-5.613
1.3.2. Quick Ratio

Measures if Sonnet Biotherapeutics Holdings Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sonnet Biotherapeutics Holdings Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.21 means the company can pay off $1.21 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is 1.211. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.122. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.211TTM1.122+0.089
TTM1.122YOY0.909+0.213
TTM1.1225Y1.124-0.001
5Y1.12410Y0.619+0.505
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2113.629-2.418
TTM1.1224.065-2.943
YOY0.9095.390-4.481
5Y1.1245.993-4.869
10Y0.6196.277-5.658

1.4. Solvency of Sonnet Biotherapeutics Holdings Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sonnet Biotherapeutics Holdings Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sonnet Biotherapeutics Holdings Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.52 means that Sonnet Biotherapeutics Holdings Inc assets are financed with 51.8% credit (debt) and the remaining percentage (100% - 51.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is 0.518. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.704. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.518TTM0.704-0.186
TTM0.704YOY1.120-0.417
TTM0.7045Y0.985-0.281
5Y0.98510Y0.776+0.209
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5180.332+0.186
TTM0.7040.333+0.371
YOY1.1200.268+0.852
5Y0.9850.366+0.619
10Y0.7760.390+0.386
1.4.2. Debt to Equity Ratio

Measures if Sonnet Biotherapeutics Holdings Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sonnet Biotherapeutics Holdings Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 107.5% means that company has $1.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sonnet Biotherapeutics Holdings Inc:

  • The MRQ is 1.075. The company is able to pay all its debts with equity. +1
  • The TTM is 1.122. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.075TTM1.122-0.048
TTM1.122YOY2.391-1.268
TTM1.1225Y2.528-1.406
5Y2.52810Y2.026+0.502
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0750.380+0.695
TTM1.1220.389+0.733
YOY2.3910.334+2.057
5Y2.5280.432+2.096
10Y2.0260.465+1.561

2. Market Valuation of Sonnet Biotherapeutics Holdings Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sonnet Biotherapeutics Holdings Inc generates.

  • Above 15 is considered overpriced but always compare Sonnet Biotherapeutics Holdings Inc to the Biotechnology industry mean.
  • A PE ratio of -1.41 means the investor is paying $-1.41 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sonnet Biotherapeutics Holdings Inc:

  • The EOD is -1.471. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.414. Based on the earnings, the company is expensive. -2
  • The TTM is -0.539. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.471MRQ-1.414-0.057
MRQ-1.414TTM-0.539-0.875
TTM-0.539YOY-0.093-0.446
TTM-0.5395Y-0.256-0.283
5Y-0.25610Y-1.126+0.871
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.471-2.426+0.955
MRQ-1.414-2.552+1.138
TTM-0.539-2.656+2.117
YOY-0.093-4.143+4.050
5Y-0.256-6.252+5.996
10Y-1.126-6.108+4.982
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sonnet Biotherapeutics Holdings Inc:

  • The EOD is -0.556. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.534. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.279. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.556MRQ-0.534-0.021
MRQ-0.534TTM-0.279-0.255
TTM-0.279YOY-0.102-0.177
TTM-0.2795Y0.119-0.398
5Y0.11910Y-1.230+1.349
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.556-3.199+2.643
MRQ-0.534-3.259+2.725
TTM-0.279-3.552+3.273
YOY-0.102-5.617+5.515
5Y0.119-8.326+8.445
10Y-1.230-8.689+7.459
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sonnet Biotherapeutics Holdings Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.57 means the investor is paying $2.57 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sonnet Biotherapeutics Holdings Inc:

  • The EOD is 2.672. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.569. Based on the equity, the company is underpriced. +1
  • The TTM is -8.925. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD2.672MRQ2.569+0.103
MRQ2.569TTM-8.925+11.494
TTM-8.925YOY-0.379-8.546
TTM-8.9255Y-0.013-8.913
5Y-0.01310Y0.417-0.429
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6721.947+0.725
MRQ2.5692.116+0.453
TTM-8.9252.095-11.020
YOY-0.3792.836-3.215
5Y-0.0133.443-3.456
10Y0.4173.791-3.374
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sonnet Biotherapeutics Holdings Inc.

3.1. Institutions holding Sonnet Biotherapeutics Holdings Inc

Institutions are holding 3.527% of the shares of Sonnet Biotherapeutics Holdings Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Renaissance Technologies Corp1.42530.00014374924700129.6656
2023-12-31Vanguard Group Inc0.47970147261000.6837
2023-12-31Tower Research Capital LLC0.06820.0001209420940
2023-12-31BlackRock Inc0.0194059400
2023-12-31Morgan Stanley - Brokerage Accounts0.002061-81-57.0423
2023-12-31Advisor Group Holdings, Inc.0.001504500
2023-12-31Wells Fargo & Co0.00070211090.9091
2023-12-31JPMorgan Chase & Co0.0006019190
2023-12-31Private Wealth Management Group LLC0.00010330
2023-09-30McCollum Christoferson Group LLC000-1841-100
2023-09-30State Street Corporation000-4295-100
2023-09-30Susquehanna International Group, LLP000-798-100
2023-09-30Northern Trust Corp000-811-100
2023-09-30Virtu Financial LLC000-3937-100
2023-09-30XTX Topco Ltd000-1024-100
2023-09-30HRT FINANCIAL LLC000-1245-100
2023-09-30Sabby Management LLC000-149579-100
2023-09-30FMR Inc00000
2023-12-31Citigroup Inc000-3-100
2023-12-31UBS Group AG000-3713-100
Total 1.99750.000261312-140401-229.0%

3.2. Funds holding Sonnet Biotherapeutics Holdings Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Cinvest Azero Global FI0.57011.47011750000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.479701472600
2024-02-29Fidelity Extended Market Index0.20770637400
2024-02-29Fidelity Series Total Market Index0.09070278500
2023-12-31NT Ext Equity Mkt Idx Fd - L0.024073600
2023-12-31Northern Trust Extended Eq Market Idx0.024073600
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.002407500
2023-09-30BlackRock Extended Mkt Composite0.0024074712366.6667
2023-12-31SSgA U.S. Extended Market Index Class I0.002307200
2024-03-31State St US Extended Mkt Indx NL Cl C0.002307200
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.00206000
2024-02-29Spartan Total Market Index Pool E0.001504600
2023-12-31SSgA U.S. Total Market Index Strategy0.000702100
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00010200
2023-08-31iShares Core S&P Total US Stock Mkt ETF00200
Total 1.40991.470143281+71+0.2%

3.3. Insider Transactions

Insiders are holding 11.737% of the shares of Sonnet Biotherapeutics Holdings Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-06-14Susan DexterBUY45415.4
2023-05-30Albert D DyrnessBUY105710.34
2023-05-17Nailesh BhattBUY11365.06
2023-05-15Pankaj MohanBUY168904.84

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Sonnet Biotherapeutics Holdings Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7510.457+64%-1.623+316%-0.072+110%-0.047+106%
Book Value Per Share--0.6770.867-22%0.262+158%1.140-41%1.681-60%
Current Ratio--1.7421.442+21%1.152+51%1.298+34%0.770+126%
Debt To Asset Ratio--0.5180.704-26%1.120-54%0.985-47%0.776-33%
Debt To Equity Ratio--1.0751.122-4%2.391-55%2.528-57%2.026-47%
Dividend Per Share----0%-0%0.029-100%0.016-100%
Eps---0.308-1.160+277%-2.367+669%-2.519+719%-1.417+360%
Free Cash Flow Per Share---0.814-1.496+84%-2.141+163%-1.569+93%-0.842+3%
Free Cash Flow To Equity Per Share--0.1970.096+105%-1.442+833%0.009+2005%0.030+563%
Gross Profit Margin--1.0001.0000%1.0000%1.009-1%1.0050%
Intrinsic Value_10Y_max--16.342--------
Intrinsic Value_10Y_min---54.225--------
Intrinsic Value_1Y_max---2.647--------
Intrinsic Value_1Y_min---7.320--------
Intrinsic Value_3Y_max---4.687--------
Intrinsic Value_3Y_min---20.490--------
Intrinsic Value_5Y_max---2.791--------
Intrinsic Value_5Y_min---31.912--------
Market Cap5555831.200-19%6608090.2204502839.255+47%2513936.880+163%4179454.239+58%8490778.607-22%
Net Profit Margin---62.735-106.038+69%-119.863+91%-47.979-24%-24.101-62%
Operating Margin---68.661-106.018+54%-120.271+75%-48.065-30%-24.144-65%
Operating Ratio--69.661108.134-36%144.218-52%50.133+39%25.402+174%
Pb Ratio2.672+4%2.569-8.925+447%-0.379+115%-0.013+100%0.417+516%
Pe Ratio-1.471-4%-1.414-0.539-62%-0.093-93%-0.256-82%-1.126-20%
Price Per Share1.810+4%1.7401.364+28%0.819+112%1.328+31%1.630+7%
Price To Free Cash Flow Ratio-0.556-4%-0.534-0.279-48%-0.102-81%0.119-549%-1.230+130%
Price To Total Gains Ratio2.410+4%2.317-0.186+108%-1.290+156%27.953-92%18.554-88%
Quick Ratio--1.2111.122+8%0.909+33%1.124+8%0.619+96%
Return On Assets---0.219-0.429+96%-0.998+356%-0.834+281%-0.448+105%
Return On Equity---0.454-0.666+47%-2.821+521%-2.867+531%-1.516+234%
Total Gains Per Share--0.7510.457+64%-1.623+316%-0.042+106%-0.032+104%
Usd Book Value--2572459.0002783398.500-8%805396.750+219%3572125.400-28%9435858.000-73%
Usd Book Value Change Per Share--0.7510.457+64%-1.623+316%-0.072+110%-0.047+106%
Usd Book Value Per Share--0.6770.867-22%0.262+158%1.140-41%1.681-60%
Usd Dividend Per Share----0%-0%0.029-100%0.016-100%
Usd Eps---0.308-1.160+277%-2.367+669%-2.519+719%-1.417+360%
Usd Free Cash Flow---3091737.000-4740414.500+53%-6571644.000+113%-4853086.050+57%-2865744.800-7%
Usd Free Cash Flow Per Share---0.814-1.496+84%-2.141+163%-1.569+93%-0.842+3%
Usd Free Cash Flow To Equity Per Share--0.1970.096+105%-1.442+833%0.009+2005%0.030+563%
Usd Market Cap5555831.200-19%6608090.2204502839.255+47%2513936.880+163%4179454.239+58%8490778.607-22%
Usd Price Per Share1.810+4%1.7401.364+28%0.819+112%1.328+31%1.630+7%
Usd Profit---1168509.000-3615916.750+209%-7264800.750+522%-5386499.900+361%-3784488.750+224%
Usd Revenue--18626.00032294.000-42%64349.750-71%1553260.900-99%5738701.750-100%
Usd Total Gains Per Share--0.7510.457+64%-1.623+316%-0.042+106%-0.032+104%
 EOD+4 -4MRQTTM+27 -6YOY+30 -35Y+23 -1310Y+19 -17

4.2. Fundamental Score

Let's check the fundamental score of Sonnet Biotherapeutics Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.471
Price to Book Ratio (EOD)Between0-12.672
Net Profit Margin (MRQ)Greater than0-62.735
Operating Margin (MRQ)Greater than0-68.661
Quick Ratio (MRQ)Greater than11.211
Current Ratio (MRQ)Greater than11.742
Debt to Asset Ratio (MRQ)Less than10.518
Debt to Equity Ratio (MRQ)Less than11.075
Return on Equity (MRQ)Greater than0.15-0.454
Return on Assets (MRQ)Greater than0.05-0.219
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Sonnet Biotherapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.938
Ma 20Greater thanMa 502.016
Ma 50Greater thanMa 1001.839
Ma 100Greater thanMa 2001.665
OpenGreater thanClose2.010
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  19-118018018-19-1



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets5,338
Total Liabilities2,765
Total Stockholder Equity2,572
 As reported
Total Liabilities 2,765
Total Stockholder Equity+ 2,572
Total Assets = 5,338

Assets

Total Assets5,338
Total Current Assets4,624
Long-term Assets714
Total Current Assets
Cash And Cash Equivalents 3,021
Net Receivables 194
Other Current Assets 1,408
Total Current Assets  (as reported)4,624
Total Current Assets  (calculated)4,624
+/-0
Long-term Assets
Property Plant Equipment 207
Long-term Assets Other 507
Long-term Assets  (as reported)714
Long-term Assets  (calculated)714
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,654
Long-term Liabilities111
Total Stockholder Equity2,572
Total Current Liabilities
Short-term Debt 76
Accounts payable 1,655
Other Current Liabilities 923
Total Current Liabilities  (as reported)2,654
Total Current Liabilities  (calculated)2,654
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt111
Long-term Liabilities  (as reported)111
Long-term Liabilities  (calculated)111
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -111,412
Other Stockholders Equity 113,984
Total Stockholder Equity (as reported)2,572
Total Stockholder Equity (calculated)2,572
+/-0
Other
Capital Stock0
Cash and Short Term Investments 3,021
Common Stock Shares Outstanding 3,798
Liabilities and Stockholders Equity 5,338
Net Debt -2,835
Net Invested Capital 2,572
Net Working Capital 1,969
Property Plant and Equipment Gross 207
Short Long Term Debt Total 187



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-09-302010-03-312009-09-302009-06-302009-03-312008-03-312007-09-302006-09-302006-06-30
> Total Assets 
2,649
2,695
5,242
3,927
2,154
2,525
2,225
1,482
1,565,923
1,601,433
1,556
2,165,614
4,799
6,084
9,094
8,252
7,646
6,694
8,989
16,028
20,088
25,756
29,169
40,499
35,792
43,358
42,772
42,611
42,205
42,205
36,574
34,121
33,486
33,215
33,057
31,565
30,183
28,966
30,507
29,766
29,793
29,793
45,424
41,847
957
31,319
3,881
7,994
3,033
7,626
7,176
28,994
20,741
15,046
7,490
5,830
4,943
13,311
10,035
5,429
5,338
5,3385,42910,03513,3114,9435,8307,49015,04620,74128,9947,1767,6263,0337,9943,88131,31995741,84745,42429,79329,79329,76630,50728,96630,18331,56533,05733,21533,48634,12136,57442,20542,20542,61142,77243,35835,79240,49929,16925,75620,08816,0288,9896,6947,6468,2529,0946,0844,7992,165,6141,5561,601,4331,565,9231,4822,2252,5252,1543,9275,2422,6952,649
   > Total Current Assets 
180
90
232
26
35
972
527
181
60,883
361,578
227
464,868
642
637
4,097
2,564
2,030
1,139
3,671
4,332
1,713
1,815
1,578
1,915
1,469
4,750
4,377
3,061
3,819
3,819
4,410
2,124
1,794
1,571
2,489
2,345
1,800
3,584
5,292
2,187
1,675
1,675
1,769
3,460
909
1,818
3,502
7,638
2,699
7,398
6,972
28,812
20,584
14,916
7,169
5,414
4,598
13,046
9,633
4,738
4,624
4,6244,7389,63313,0464,5985,4147,16914,91620,58428,8126,9727,3982,6997,6383,5021,8189093,4601,7691,6751,6752,1875,2923,5841,8002,3452,4891,5711,7942,1244,4103,8193,8193,0614,3774,7501,4691,9151,5781,8151,7134,3323,6711,1392,0302,5644,097637642464,868227361,57860,883181527972352623290180
       Cash And Cash Equivalents 
156
53
210
1
28
284
41
119
12,305
170,506
2
223,857
165
182
3,568
1,695
1,248
389
161
213
443
476
273
323
246
3,325
2,808
1,806
1,528
1,528
983
991
269
278
378
295
273
411
1,485
1,092
630
630
579
637
889
549
3,107
7,350
2,348
6,739
6,038
27,622
19,410
13,636
5,225
3,053
1,701
11,390
7,021
2,274
3,021
3,0212,2747,02111,3901,7013,0535,22513,63619,41027,6226,0386,7392,3487,3503,1075498896375796306301,0921,4854112732953782782699919831,5281,5281,8062,8083,3252463232734764432131613891,2481,6953,568182165223,8572170,50612,3051194128428121053156
       Short-term Investments 
0
0
0
0
0
483
385
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35
35
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000353500000000000000038548300000
       Net Receivables 
24
38
22
25
0
12
8
14
2,482
20,925
42
66,667
109
30
78
120
161
72
135
156
227
174
118
386
277
309
413
195
882
882
831
223
524
349
330
275
476
345
642
365
387
387
519
224
132
63
0
0
0
0
0
0
0
0
0
0
1,336
447
749
787
194
1947877494471,33600000000006313222451938738736564234547627533034952422383188288219541330927738611817422715613572161120783010966,6674220,9252,48214812025223824
       Other Current Assets 
0
0
0
0
7
193
93
48
46,096
170,147
0
174,344
0
305
310
569
0
499
0
3,764
495
570
711
664
331
464
564
467
636
480
2,097
392
461
424
1,221
1,310
20,425
2,440
19,799
323
17,830
17,757
250
2,245
19
934
395
288
351
659
934
1,189
1,174
1,280
1,944
2,361
2,897
1,209
1,863
1,677
1,408
1,4081,6771,8631,2092,8972,3611,9441,2801,1741,189934659351288395934192,24525017,75717,83032319,7992,44020,4251,3101,2214244613922,0974806364675644643316647115704953,764049905693103050174,3440170,14746,096489319370000
   > Long-term Assets 
37
35
31
44
2,120
1,553
1,697
1,301
1,505,040
1,239,855
1,329
1,700,746
4,157
5,447
4,997
5,689
5,616
5,555
5,319
11,696
18,374
23,941
27,591
38,584
34,323
38,608
38,396
39,550
38,387
38,387
32,164
31,997
31,692
31,644
30,568
29,220
8,549
25,381
25,216
27,579
10,468
28,118
43,654
38,387
48
29,501
379
357
334
227
203
182
157
131
321
416
345
265
402
691
714
71469140226534541632113115718220322733435737929,5014838,38743,65428,11810,46827,57925,21625,3818,54929,22030,56831,64431,69231,99732,16438,38738,38739,55038,39638,60834,32338,58427,59123,94118,37411,6965,3195,5555,6165,6894,9975,4474,1571,700,7461,3291,239,8551,505,0401,3011,6971,5532,12044313537
       Property Plant Equipment 
37
35
31
44
34
31
31
33
27,473
23,013
21
17,990
1,505
2,747
2,043
2,423
2,316
2,227
2,127
5,047
5,620
8,523
12,697
14,592
13,315
14,993
14,573
17,855
16,641
16,410
11,600
11,531
11,514
11,499
10,343
9,006
8,549
8,204
8,236
9,532
10,468
10,157
26,725
22,684
48
16,582
296
274
251
227
203
182
157
131
321
303
284
265
247
227
207
20722724726528430332113115718220322725127429616,5824822,68426,72510,15710,4689,5328,2368,2048,5499,00610,34311,49911,51411,53111,60016,41016,64117,85514,57314,99313,31514,59212,6978,5235,6205,0472,1272,2272,3162,4232,0432,7471,50517,9902123,01327,4733331313444313537
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
396
0
0
0
396
396
396
2,054
6,497
9,168
9,182
18,192
15,617
15,446
15,812
12,270
12,702
12,702
12,569
12,518
12,406
12,438
12,541
12,604
12,648
10,164
10,127
11,335
11,280
11,280
11,275
10,499
8,568
8,513
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000008,5138,56810,49911,27511,28011,28011,33510,12710,16412,64812,60412,54112,43812,40612,51812,56912,70212,70212,27015,81215,44615,61718,1929,1829,1686,4972,054396396396000396000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,492
2,551
1,585
0
1,585
1,585
1,585
1,585
1,081
1,079
1,061
0
800
800
800
800
0
0
0
0
0
0
0
0
0
390
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000039000000000080080080080001,0611,0791,0811,5851,5851,5851,58501,5852,5512,49200000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
325
776
968
933
560
630
624
2,399
3,425
3,408
3,609
3,752
3,397
6,097
6,024
7,542
7,282
7,282
6,636
6,572
6,530
6,442
6,374
6,311
5,897
5,760
5,600
5,463
5,123
5,123
4,888
4,480
3,657
3,565
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000003,5653,6574,4804,8885,1235,1235,4635,6005,7605,8976,3116,3746,4426,5306,5726,6367,2827,2827,5426,0246,0973,3973,7523,6093,4083,4252,399624630560933968776325000000000000
       Long-term Assets Other 
0
0
0
0
2,042
1,478
1,628
1,152
1,171,594
878,342
883
1,577,138
348
1,712
1,905
2,279
344
2,268
171
2,184
-167
-158
2,068
2,013
1,958
2,037
1,951
1,847
1,730
1,730
1,347
1,365
443
466
510
499
490
1,253
453
1,249
447
447
402
351
-12,225
149
83
83
83
166
0
0
0
0
-321
113
60
-265
155
464
507
507464155-26560113-3210000166838383149-12,2253514024474471,2494531,2534904995104664431,3651,3471,7301,7301,8471,9512,0371,9582,0132,068-158-1672,1841712,2683442,2791,9051,7123481,577,138883878,3421,171,5941,1521,6281,4782,0420000
> Total Liabilities 
106
168
352
420
1,053
1,060
726
1,025
1,143,615
565,291
638
1,788,694
4,313
5,013
1,954
1,837
2,118
1,888
4,847
6,823
8,849
10,688
13,609
20,038
20,819
21,699
21,158
18,392
20,448
20,448
21,112
18,690
20,922
19,873
19,384
19,031
19,477
19,890
20,971
20,599
22,363
22,363
38,500
36,714
3,357
34,274
3,501
4,974
5,520
5,603
5,807
6,734
4,350
6,513
6,725
8,369
8,480
7,943
6,616
5,655
2,765
2,7655,6556,6167,9438,4808,3696,7256,5134,3506,7345,8075,6035,5204,9743,50134,2743,35736,71438,50022,36322,36320,59920,97119,89019,47719,03119,38419,87320,92218,69021,11220,44820,44818,39221,15821,69920,81920,03813,60910,6888,8496,8234,8471,8882,1181,8371,9545,0134,3131,788,694638565,2911,143,6151,0257261,0601,053420352168106
   > Total Current Liabilities 
6
4
282
419
1,053
1,060
726
750
707,115
565,291
638
1,550,668
3,720
4,779
1,355
1,478
1,773
1,623
4,603
5,288
5,532
6,583
9,310
10,693
11,413
11,119
13,664
8,212
16,181
16,181
17,329
14,892
12,111
6,360
6,280
6,444
14,906
15,455
15,853
16,635
14,312
14,312
19,880
19,000
3,357
18,205
3,230
4,724
5,292
5,398
5,752
6,703
4,345
6,513
6,505
8,165
8,293
7,774
6,466
5,525
2,654
2,6545,5256,4667,7748,2938,1656,5056,5134,3456,7035,7525,3985,2924,7243,23018,2053,35719,00019,88014,31214,31216,63515,85315,45514,9066,4446,2806,36012,11114,89217,32916,18116,1818,21213,66411,11911,41310,6939,3106,5835,5325,2884,6031,6231,7731,4781,3554,7793,7201,550,668638565,291707,1157507261,0601,05341928246
       Short-term Debt 
0
0
0
380
500
600
350
412
412,500
249,455
248
1,301,723
1,172
3,911
47
274
28
267
31
673
700
1,475
2,018
2,178
1,814
997
3,520
1,397
5,383
5,383
9,665
9,757
6,172
800
929
775
5,742
8,957
6,158
9,333
3,740
3,740
10,214
9,923
1
9,531
105
103
86
89
92
95
99
80
52
52
52
69
70
73
76
767370695252528099959289861031059,53119,92310,2143,7403,7409,3336,1588,9575,7427759298006,1729,7579,6655,3835,3831,3973,5209971,8142,1782,0181,4757006733126728274473,9111,1721,301,723248249,455412,500412350600500380000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
6,348
26
21
1
1
1
1
1
1
1
1
1
1
0
0
0
000111111111121266,348100000000000000000000000000000000000000000000
       Accounts payable 
6
4
25
39
194
172
176
205
200,133
225,854
0
191,821
0
327
923
0
0
0
0
0
2,437
2,717
3,584
0
6,879
7,244
7,485
4,633
5,909
7,045
5,612
0
5,747
5,460
5,235
5,579
6,164
6,497
6,695
7,302
7,572
8,453
9,665
7,432
3,207
4,634
2,422
2,058
2,259
1,914
2,151
3,781
2,112
4,036
3,019
4,752
4,574
4,500
3,024
2,202
1,655
1,6552,2023,0244,5004,5744,7523,0194,0362,1123,7812,1511,9142,2592,0582,4224,6343,2077,4329,6658,4537,5727,3026,6956,4976,1645,5795,2355,4605,74705,6127,0455,9094,6337,4857,2446,87903,5842,7172,437000009233270191,8210225,854200,133205176172194392546
       Other Current Liabilities 
0
0
0
0
56
80
86
123
90,107
89,982
0
57,124
0
524
385
1,204
0
1,356
0
4,614
190
110
7,292
8,515
296
547
10,119
6,815
808
863
7,665
5,136
174
5,560
107
5,669
0
5,261
0
6,107
0
3,750
8,658
8,093
-811
826
782
2,064
2,447
2,896
2,509
2,310
1,747
2,105
3,204
3,194
3,538
3,112
3,315
3,231
923
9233,2313,3153,1123,5383,1943,2042,1051,7472,3102,5092,8962,4472,064782826-8118,0938,6583,75006,10705,26105,6691075,5601745,1367,6658638086,81510,1195472968,5157,2921101904,61401,35601,204385524057,124089,98290,1071238680560000
   > Long-term Liabilities 
101
164
70
2
0
0
0
275
436,500
0
0
238,026
592
233
599
359
345
265
280
1,535
2,794
3,348
4,299
9,344
7,893
8,514
7,494
10,180
4,267
4,251
3,783
3,798
3,735
13,514
8,299
12,586
3,788
4,436
3,460
3,964
7,223
4,251
18,620
17,714
17,784
16,068
271
250
228
205
55
31
5
4,408
221
204
187
169
150
131
111
1111311501691872042214,4085315520522825027116,06817,78417,71418,6204,2517,2233,9643,4604,4363,78812,5868,29913,5143,7353,7983,7834,2514,26710,1807,4948,5147,8939,3444,2993,3482,7941,535280265345359599233592238,02600436,500275000270164101
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
701
953
1,171
0
6,523
7,720
4,920
7,740
1,115
13
313
0
3,966
9,388
7,750
8,357
212
0
0
0
3,000
684
692
701
710
718
124
0
125
126
0
0
0
0
0
0
0
0
0
0
0
0000000000012612501247187107016926843,0000002128,3577,7509,3883,9660313131,1157,7404,9207,7206,52301,17195370100000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
395
421
1,764
0
0
0
0
0
0
0
0
0
349
349
0
0
0
0
0
0
0
0
0
0
0
460
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000460000000000003493490000000001,76442139500000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,285
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001,285000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,395
3,151
3,128
0
2,883
2,859
2,574
2,440
3,152
2,910
3,470
0
3,447
3,537
3,766
3,598
2,936
3,787
3,460
3,297
3,548
1,235
1,127
120
102
102
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001021021201,1271,2353,5483,2973,4603,7872,9363,5983,7663,5373,44703,4702,9103,1522,4402,5742,8592,88303,1283,1512,39500000000000000000000
> Total Stockholder Equity
2,543
2,527
4,890
3,507
1,102
1,465
1,498
457
422,308
1,036,142
0
376,920
0
1,071
7,140
6,415
0
4,805
0
9,205
11,239
15,069
15,560
20,462
10,068
16,896
21,614
24,219
21,367
20,138
15,462
15,431
12,564
12,035
13,673
11,629
10,706
8,377
9,537
8,246
7,430
5,937
6,014
4,648
-2,400
-3,539
380
3,020
-2,487
2,022
1,369
22,260
16,391
8,533
764
-2,539
-3,537
5,369
3,418
-226
2,572
2,572-2263,4185,369-3,537-2,5397648,53316,39122,2601,3692,022-2,4873,020380-3,539-2,4004,6486,0145,9377,4308,2469,5378,37710,70611,62913,67312,03512,56415,43115,46220,13821,36724,21921,61416,89610,06820,46215,56015,06911,2399,20504,80506,4157,1401,0710376,92001,036,142422,3084571,4981,4651,1023,5074,8902,5272,543
   Common Stock
0
1
0
1
1
1
0
0
127
298
0
301
0
0
0
0
0
0
0
0
1
1
1
0
1
1
1
2
2
2
2
2
2
349
0
0
0
0
0
0
0
0
1
1
12,510
1
1
1
2
2
2
6
6
6
6
1
1
2
4
0
0
004211666622211112,5101100000000349222222111011100000000301029812700111010
   Retained Earnings Total Equity00000000000-48,622-42,5820-29,185-77,344-75,068-66,183-62,270-59,026-57,125-54,831-53,565-52,777-49,109-46,943-45,357-43,958-42,2060-39,627-34,438-33,013-30,607-26,124-23,144-20,8760-17,334-15,923-14,47300000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
16
-156
51
-64
0
-168
-182
-192
-164
-156
-88
-64
-30
147
-2,000
-3,000
-3,123
-912
-1,000
-1,000
-1,163
-1,248
-1,000
-1,109
-1,000
-935
-1,000
-110
-107
-141
-202
-202
-232
-392
0
-128
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000-1280-392-232-202-202-141-107-110-1,000-935-1,000-1,109-1,000-1,248-1,163-1,000-1,000-912-3,123-3,000-2,000147-30-64-88-156-164-192-182-1680-6451-156160000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,405
30,634
31,160
0
32,601
42,983
46,040
55,208
55,366
55,366
55,739
0
55,924
57,099
59,997
59,506
60,750
61,264
63,208
63,217
64,757
65,126
71,210
71,222
71,506
73,471
29,564
0
40,094
50,642
0
0
0
0
0
0
0
0
0
0
0
0000000000050,64240,094029,56473,47171,50671,22271,21065,12664,75763,21763,20861,26460,75059,50659,99757,09955,924055,73955,36655,36655,20846,04042,98332,601031,16030,63425,40500000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
2,543
2,527
4,890
3,506
4,642
4,642
4,713
4,641
4,834,431
5,739,555
0
5,802,074
0
7,672
14,779
14,794
0
14,802
0
21,332
-88
-64
32,894
38,347
-1,658
-2,944
50,859
55,736
-988
-791
56,249
56,960
-1,156
56,163
-966
58,875
-935
60,615
-107
62,551
-202
-164
67,824
70,521
-46
73,471
29,564
39,724
40,094
50,642
56,103
83,943
84,275
84,626
84,734
88,872
93,415
107,987
109,982
110,018
113,984
113,984110,018109,982107,98793,41588,87284,73484,62684,27583,94356,10350,64240,09439,72429,56473,471-4670,52167,824-164-20262,551-10760,615-93558,875-96656,163-1,15656,96056,249-791-98855,73650,859-2,944-1,65838,34732,894-64-8821,332014,802014,79414,7797,67205,802,07405,739,5554,834,4314,6414,7134,6424,6423,5064,8902,5272,543



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue148
Cost of Revenue-76
Gross Profit7272
 
Operating Income (+$)
Gross Profit72
Operating Expense-18,940
Operating Income-18,793-18,868
 
Operating Expense (+$)
Research Development11,815
Selling General Administrative7,126
Selling And Marketing Expenses0
Operating Expense18,94018,940
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-18,793
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-18,833-18,753
EBIT - interestExpense = -18,753
-18,793
-18,833
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-18,753-18,833
Earnings Before Interest and Taxes (EBITDA)-18,677
 
After tax Income (+$)
Income Before Tax-18,833
Tax Provision-0
Net Income From Continuing Ops-18,833-18,833
Net Income-18,833
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses18,940
Total Other Income/Expenses Net-400
 

Technical Analysis of Sonnet Biotherapeutics Holdings Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sonnet Biotherapeutics Holdings Inc. The general trend of Sonnet Biotherapeutics Holdings Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sonnet Biotherapeutics Holdings Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sonnet Biotherapeutics Holdings Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.18 < 2.3399 < 2.6099.

The bearish price targets are: 1.8 > 1.65 > 1.5334.

Tweet this
Sonnet Biotherapeutics Holdings Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sonnet Biotherapeutics Holdings Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sonnet Biotherapeutics Holdings Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sonnet Biotherapeutics Holdings Inc. The current macd is 0.01931953.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sonnet Biotherapeutics Holdings Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Sonnet Biotherapeutics Holdings Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Sonnet Biotherapeutics Holdings Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Sonnet Biotherapeutics Holdings Inc Daily Moving Average Convergence/Divergence (MACD) ChartSonnet Biotherapeutics Holdings Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sonnet Biotherapeutics Holdings Inc. The current adx is 28.24.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sonnet Biotherapeutics Holdings Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Sonnet Biotherapeutics Holdings Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sonnet Biotherapeutics Holdings Inc. The current sar is 2.3399.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Sonnet Biotherapeutics Holdings Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sonnet Biotherapeutics Holdings Inc. The current rsi is 42.94. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Sonnet Biotherapeutics Holdings Inc Daily Relative Strength Index (RSI) ChartSonnet Biotherapeutics Holdings Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sonnet Biotherapeutics Holdings Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sonnet Biotherapeutics Holdings Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Sonnet Biotherapeutics Holdings Inc Daily Stochastic Oscillator ChartSonnet Biotherapeutics Holdings Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sonnet Biotherapeutics Holdings Inc. The current cci is -129.45899227.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Sonnet Biotherapeutics Holdings Inc Daily Commodity Channel Index (CCI) ChartSonnet Biotherapeutics Holdings Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sonnet Biotherapeutics Holdings Inc. The current cmo is -28.26118954.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Sonnet Biotherapeutics Holdings Inc Daily Chande Momentum Oscillator (CMO) ChartSonnet Biotherapeutics Holdings Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sonnet Biotherapeutics Holdings Inc. The current willr is -97.2972973.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Sonnet Biotherapeutics Holdings Inc Daily Williams %R ChartSonnet Biotherapeutics Holdings Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sonnet Biotherapeutics Holdings Inc.

Sonnet Biotherapeutics Holdings Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sonnet Biotherapeutics Holdings Inc. The current atr is 0.15703154.

Sonnet Biotherapeutics Holdings Inc Daily Average True Range (ATR) ChartSonnet Biotherapeutics Holdings Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sonnet Biotherapeutics Holdings Inc. The current obv is 16,482,640.

Sonnet Biotherapeutics Holdings Inc Daily On-Balance Volume (OBV) ChartSonnet Biotherapeutics Holdings Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sonnet Biotherapeutics Holdings Inc. The current mfi is 30.58.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Sonnet Biotherapeutics Holdings Inc Daily Money Flow Index (MFI) ChartSonnet Biotherapeutics Holdings Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sonnet Biotherapeutics Holdings Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Sonnet Biotherapeutics Holdings Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sonnet Biotherapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.938
Ma 20Greater thanMa 502.016
Ma 50Greater thanMa 1001.839
Ma 100Greater thanMa 2001.665
OpenGreater thanClose2.010
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sonnet Biotherapeutics Holdings Inc with someone you think should read this too:
  • Are you bullish or bearish on Sonnet Biotherapeutics Holdings Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sonnet Biotherapeutics Holdings Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sonnet Biotherapeutics Holdings Inc

I send you an email if I find something interesting about Sonnet Biotherapeutics Holdings Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Sonnet Biotherapeutics Holdings Inc.

Receive notifications about Sonnet Biotherapeutics Holdings Inc in your mailbox!